Answer Questions about Andexxa, the New Apixaban and Rivaroxaban Reversal Agent
You'll hear about Andexxa (an-DEK-sah, inactivated recombinant factor Xa), the new, IV direct oral anticoagulant (DOAC) reversal agent.
Andexxa binds and inactivates factor Xa inhibitors...compared to idarucizumab (Praxbind), which reverses dabigatran (Pradaxa).
Andexxa's FDA approval is based on quick reversal of clotting time in patients taking apixaban and rivaroxaban. But it's also being studied with other anticoagulants...betrixaban (Bevyxxa), edoxaban (Savaysa), and enoxaparin.